Prospective Observational Study of Bisphosphonate-Related Osteonecrosis of the Jaw in Multiple Myeloma: Microbiota Profiling and Cytokine Expression.
bisphosphanates
cytokines
microbiome
multiple myeloma
osteonecrosis of the jaw
Journal
Frontiers in oncology
ISSN: 2234-943X
Titre abrégé: Front Oncol
Pays: Switzerland
ID NLM: 101568867
Informations de publication
Date de publication:
2021
2021
Historique:
received:
03
05
2021
accepted:
01
06
2021
entrez:
12
7
2021
pubmed:
13
7
2021
medline:
13
7
2021
Statut:
epublish
Résumé
Define incidence and risk factors of osteonecrosis of the jaw (ONJ) and explore oral microbial signatures and host immune response as reflected by cytokine changes in saliva and serum in multiple myeloma (MM) patients on bisphosphate (BP) therapy. A single center observational prospective study of MM patients (n = 110) on >2 years of BP, none had ONJ at enrollment. Patients were followed every 3 months for 18 months with clinical/dental examination and serial measurements of inflammatory cytokines, bone turnover markers, and angiogenic growth factors. Oral microbiota was characterized by sequencing of 16S rRNA gene from saliva. Over the study period 14 patients (13%) developed BRONJ, at a median of 5.7 years (95% CI: 1.9-12.0) from MM diagnosis. Chronic periodontal disease was the main clinically observed risk factor. Oral microbial profiling revealed lower bacterial richness/diversity in BRONJ. Periodontal disease associated with low microbial diversity and predominance of invasive species with a proinflammatory cytokine profile leading to tissue damage and alteration of immunity seems to be the main culprit in pathogenesis of BRONJ.
Identifiants
pubmed: 34249765
doi: 10.3389/fonc.2021.704722
pmc: PMC8263936
doi:
Types de publication
Journal Article
Langues
eng
Pagination
704722Informations de copyright
Copyright © 2021 Badros, Meddeb, Weikel, Philip, Milliron, Lapidus, Hester, Goloubeva, Meiller and Mongodin.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Bone. 2019 Jun;123:234-245
pubmed: 30953717
J Clin Oncol. 2006 Feb 20;24(6):945-52
pubmed: 16484704
J Transl Med. 2015 Jul 04;13:212
pubmed: 26141514
Oral Surg Oral Med Oral Pathol Oral Radiol. 2015 Dec;120(6):699-706
pubmed: 26455289
Infect Immun. 2016 Sep 19;84(10):2802-12
pubmed: 27456834
Nat Rev Immunol. 2008 Dec;8(12):958-69
pubmed: 19029990
Lancet Oncol. 2018 Mar;19(3):370-381
pubmed: 29429912
Cochrane Database Syst Rev. 2017 Oct 06;10:CD012432
pubmed: 28983908
J Craniomaxillofac Surg. 2017 Mar;45(3):357-363
pubmed: 28162845
J Bone Miner Res. 2017 Feb;32(2):309-318
pubmed: 27567012
J Immunol Res. 2018 Jan 14;2018:8917804
pubmed: 29507865
PLoS One. 2012;7(6):e37919
pubmed: 22675498
J Oral Maxillofac Surg. 2008 Apr;66(4):767-75
pubmed: 18355603
Arch Oral Biol. 2014 Aug;59(8):790-9
pubmed: 24859766
Database (Oxford). 2010 Jul 06;2010:baq013
pubmed: 20624719
J Oral Maxillofac Surg. 2014 Oct;72(10):1938-56
pubmed: 25234529
J Oral Maxillofac Surg. 2004 May;62(5):527-34
pubmed: 15122554
Mayo Clin Proc. 2008 Sep;83(9):1032-45
pubmed: 18775204
Sci Rep. 2020 Jun 12;10(1):9546
pubmed: 32533015
J Bone Miner Res. 2015 Dec;30(12):2140-9
pubmed: 26531055
J Clin Oncol. 2009 Nov 10;27(32):5356-62
pubmed: 19805682
J Oral Maxillofac Surg. 2003 Sep;61(9):1115-7
pubmed: 12966493
PLoS One. 2013 Apr 22;8(4):e61217
pubmed: 23630581
Mol Oral Microbiol. 2014 Aug;29(4):145-55
pubmed: 24848553
PLoS One. 2012;7(7):e41065
pubmed: 22848429
Yakugaku Zasshi. 2020;140(1):63-79
pubmed: 31902887
Ann Oncol. 2012 May;23(5):1341-1347
pubmed: 21986094
Bone Res. 2020 Mar 11;8:14
pubmed: 32195012
Ann N Y Acad Sci. 2011 Feb;1218:47-54
pubmed: 20946574
Acta Clin Belg. 2018 Apr;73(2):100-109
pubmed: 28693379
J Infect Dis. 2002 Jan 1;185(1):85-90
pubmed: 11756985
Biochem Genet. 2020 Jun;58(3):473-489
pubmed: 32274606
Oral Dis. 2012 Sep;18(6):602-12
pubmed: 22443347
Clin Cancer Res. 2013 Jun 15;19(12):3176-88
pubmed: 23616636
Nat Methods. 2010 May;7(5):335-6
pubmed: 20383131
J Clin Oncol. 2008 Dec 20;26(36):5904-9
pubmed: 19018084